Qiagen N.V. (QGEN)
| Market Cap | 10.13B |
| Revenue (ttm) | 1.94B |
| Net Income (ttm) | 72.70M |
| Shares Out | 222.24M |
| EPS (ttm) | 0.33 |
| PE Ratio | 139.91 |
| Forward PE | 20.84 |
| Dividend | $1.32 (2.89%) |
| Ex-Dividend Date | Jan 30, 2024 |
| Volume | 871,863 |
| Open | 46.05 |
| Previous Close | 45.68 |
| Day's Range | 45.54 - 46.06 |
| 52-Week Range | 34.74 - 47.44 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 50.07 (+9.83%) |
| Earnings Date | Oct 28, 2024 |
About QGEN
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for n... [Read more]
Financial Performance
In 2023, Qiagen's revenue was $1.97 billion, a decrease of -8.23% compared to the previous year's $2.14 billion. Earnings were $341.30 million, a decrease of -19.35%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $50.07, which is an increase of 9.83% from the latest price.
News
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables...
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs
Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epid...
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer's disease
QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with...
QIAGEN N.V. announces conversion price of new net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...
QIAGEN N.V. announces successful placement of new net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...
QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases
New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN's syndromic testing platform QIAstat-Dx enables specialty care providers to make fast...
Qiagen N.V. (QGEN) Q2 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q2 2024 Earnings Call Transcript Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET Company Participants John Gilardi - Investor Relations Thierry Bernard - Chief Exec...
QIAGEN delivers solid performance and exceeds outlook for Q2 2024
Q2 2024: Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55 // Net sales at CER of $502 million ahead of outl...
QIAGEN N.V. to release results for Q2 2024 and hold webcast
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024.
QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children
American Academy of Pediatrics in the United States now recommends IGRA tests like QuantiFERON-TB Gold Plus to screen at-risk children of all ages // New recommendation joins trend of U.S. tuberculosi...
QIAGEN announces 2028 strategy for solid profitable growth
Hosts Capital Markets Day event in New York to outline strategy anchored by sharpened focus on growth pillars set to drive about 7% CER sales CAGR from 2024-2028 // Targeting at least 31% CER adjusted...
QIAGEN's software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs
Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flag...
QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to sustainable growth
ESG commitments recognized as strategic business investments bringing value to stakeholders, including customers and employees // Environment: 15% reduction in Scope 1 and 2 emissions in 2023 through ...
QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious disease research and surveillance
35 new wet-lab tested digital PCR Microbial DNA Detection Assays on research platform GeneGlobe target a wide range of pathogens causing tropical diseases, sexually transmitted and urine tract infecti...
QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition period
NeuMoDx 96 and NeuMoDx 288 Molecular Systems decision taken in light of challenging post-pandemic market development trends // Reaffirms Q2 2024 outlook, raises full-year 2024 outlook for adjusted dil...
QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of its research platform GeneGlobe
New QIAcuity digital PCR Custom Assay Design Tool for copy number variation analysis supports researchers' customization needs, complementing QIAGEN's existing pre-designed assays // GeneGlobe Design ...
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results...
QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiom...
Lab Instrument Industry Update - New Commercial Entrants
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry h...
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ...
QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results
QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute ...
QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics
Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law en...
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances p...
Qiagen N.V. (QGEN) Q1 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q1 2024 Earnings Conference Call April 30, 2024 9:00 AM ET Company Participants John Gilardi - VP, Corporate Communications & IR Thierry Bernard - Chief Executive Officer Rola...